← Leaderboards
Kathy Steece Steece-Collier
Michigan State University
$7,348,879
Attributed
$10,270,890
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,270,890 · 6
By mechanism
R01$8,308,740 · 3
P50$1,175,504 · 1
R56$402,896 · 1
R21$383,750 · 1
Top collaborators
- Jeffrey H Kordower7 shared
- Fredric Manfredsson7 shared
Others in their field
Top investigators on “Levodopa”
- Daniel M Corcos · Northwestern University$26,390,472
- Jerrold L Vitek · University Of Minnesota$12,616,562
- David Eidelberg · North Shore University Hospital$10,608,719
- Fay Bahling Horak · Oregon Health And Science University$9,478,895
- Stella M Papa · Emory University$8,668,977
- Dalton James Surmeier · University Of Tennessee Health Sci Ctr$8,291,606
Research focus
LevodopaParkinson DiseaseCorpus Striatum StructureParkinsonian DisordersDopamineBrainNeuronsRattusSynapsesDendritic SpinesSeveritiesDopaminergic NeuronDyskinetic SyndromeMotorTreatment EfficacyPreventBehavioralPharmacotherapyReportingMessenger RnaDopamine GraftMediatingEmbryoIndexing
Grant awards (28)
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$643,792
R01 · FY2025 · NS · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$952,368
R01 · FY2024 · NS · contact PI
Impact of Dysfunctional BDNF on Dopamine Terminal Remodeling in the Parkinsonian Striatum$324,625
R01 · FY2023 · NS · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$468,320
R01 · FY2022 · NS · contact PI
Impact of Dysfunctional BDNF on Dopamine Terminal Remodeling in the Parkinsonian Striatum$347,350
R01 · FY2022 · NS · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$568,415
R01 · FY2021 · NS · contact PI
Impact of Dysfunctional BDNF on Dopamine Terminal Remodeling in the Parkinsonian Striatum$352,660
R01 · FY2021 · NS · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$590,058
R01 · FY2020 · NS · contact PI
Impact of Dysfunctional BDNF on Dopamine Terminal Remodeling in the Parkinsonian Striatum$404,677
R01 · FY2020 · NS · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$561,645
R01 · FY2019 · NS · contact PI
Impact of Dysfunctional BDNF on Dopamine Terminal Remodeling in the Parkinsonian Striatum$355,680
R01 · FY2019 · NS · contact PI
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$598,419
R01 · FY2018 · NS · contact PI
Striatal CaV1.3 Calcium Channels: An Overlooked Antidyskinetic Target for PD$191,875
R21 · FY2016 · NS · contact PI
Striatal CaV1.3 Calcium Channels: An Overlooked Antidyskinetic Target for PD$191,875
R21 · FY2015 · NS · contact PI
"Profiles of Maladaptive Plasticity: Impact on Graft and Levodopa Efficacy"$199,983
P50 · FY2013 · NS · contact PI
"Profiles of Maladaptive Plasticity: Impact on Graft and Levodopa Efficacy"$255,922
P50 · FY2012 · NS · contact PI
Aberrant Synaptic Plasticity: Impact on Dopamine Graft Outcome$264,171
R01 · FY2011 · NS · contact PI
"Profiles of Maladaptive Plasticity: Impact on Graft and Levodopa Efficacy"$237,871
P50 · FY2011 · NS · contact PI
Aberrant Synaptic Plasticity: Impact on Dopamine Graft Outcome$50,000
R01 · FY2011 · NS · contact PI
Aberrant Synaptic Plasticity: Impact on Dopamine Graft Outcome$266,867
R01 · FY2010 · NS · contact PI
"Profiles of Maladaptive Plasticity: Impact on Graft and Levodopa Efficacy"$244,848
P50 · FY2010 · NS · contact PI
Aberrant Synaptic Plasticity: Impact on Dopamine Graft Outcome$292,305
R01 · FY2009 · NS · contact PI
"Profiles of Maladaptive Plasticity: Impact on Graft and Levodopa Efficacy"$236,880
P50 · FY2009 · NS · contact PI
Aberrant Synaptic Plasticity: Impact of Dopamine on Graft Outcome$402,896
R56 · FY2008 · NS · contact PI
LEVODOPA DYSKINESIAS: IMPACT OF DOPAMINE NEURONS$320,396
R01 · FY2006 · NS · contact PI
LEVODOPA DYSKINESIAS: IMPACT OF DOPAMINE NEURONS$328,106
R01 · FY2005 · NS
LEVODOPA DYSKINESIAS: IMPACT OF DOPAMINE NEURONS$309,938
R01 · FY2004 · NS
LEVODOPA DYSKINESIAS--IMPACT OF DOPAMINE NEURONS$308,948
R01 · FY2003 · NS